Citation: | WANG Lihua, WANG Yi, PENG Chao, RAN Dongchuan, HE Yan. Changes of tumor markers after blood glucosecontrol in patients with type 2 diabetes mellitus and influencing factors[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 91-95. DOI: 10.7619/jcmp.20200919 |
[1] |
SAEEDI P, PETERSOHN I, SALPEA P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843
|
[2] |
严宝湖, 蔡玥, 薛明, 等. 2010与2017年中国城市和农村主要慢性病可避免死亡率的比较研究[J]. 中华预防医学杂志, 2020, 54(6): 679-684. doi: 10.3760/cma.j.cn112150-20190927-00756
|
[3] |
MATTIUZZI C, LIPPI G. Current cancer epidemiology[J]. J Epidemiol Glob Health, 2019, 9(4): 217-222. doi: 10.2991/jegh.k.191008.001
|
[4] |
LUO S, LI J Y, ZHAO L N, et al. Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016, 40(1): 110-123. doi: 10.1016/j.clinre.2015.05.021
|
[5] |
LIAW Y P, KO P C, JAN S R, et al. Implications of Type1/2 diabetes mellitus in breast cancer development: a general female population-based cohort study[J]. J Cancer, 2015, 6(8): 734-739. doi: 10.7150/jca.12197
|
[6] |
GIOVANNUCCI E, HARLAN D M, ARCHER M C, et al. Diabetes and Cancer: a consensus report[J]. Diabetes Care, 2010, 33(7): 1674-1685. doi: 10.2337/dc10-0666
|
[7] |
TSILIDIS K K, KASIMIS J C, LOPEZ D S, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies[J]. BMJ, 2015, 350: g7607. doi: 10.1136/bmj.g7607
|
[8] |
PEARSON-STUTTARD J, ZHOU B, KONTIS V, et al. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment[J]. Lancet Diabetes Endocrinol, 2018, 6(6): e6-e15. doi: 10.1016/S2213-8587(18)30150-5
|
[9] |
VIGNERI P, FRASCA F, SCIACCA L, et al. Diabetes and cancer[J]. Endocr - Relat Cancer, 2009, 16(4): 1103-1123. doi: 10.1677/ERC-09-0087
|
[10] |
叶涛, 邹海珠, 陶栎箫, 等. 2型糖尿病患者血清肿瘤标志物CA19-9、CEA与HbA1c、血糖、C肽及脂类的相关分析[J]. 暨南大学学报: 自然科学与医学版, 2020, 41(1): 58-63. https://www.cnki.com.cn/Article/CJFDTOTAL-JNDX202001007.htm
|
[11] |
蒋斌, 沈山梅, 金露, 等. 2型糖尿病患者肿瘤标志物水平及其影响因素研究[J]. 中国全科医学, 2017, 20(32): 3983-3990. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX201732003.htm
|
[12] |
THOMAS P, TOTH C A, SAINI K S, et al. The structure, metabolism and function of the carcinoembryonic antigen gene family[J]. Biochim Biophys Acta, 1990, 1032(2/3): 177-189. http://www.ncbi.nlm.nih.gov/pubmed/2261493
|
[13] |
GANGULY A, YELTSIN E, ROBBINS J. Identification of a carcinoembryonic antigen binding protein on monocytes[J]. Biochem Biophys Res Commun, 2003, 311(2): 319-323. doi: 10.1016/j.bbrc.2003.09.213
|
[14] |
LEE J Y, LEE D C, LEE J W. Serum carcinoembryonic antigen is associated with non-alcoholic fatty liver disease in healthy Korean non-smokers[J]. Clin Chem Lab Med, 2013, 51(7): 1499-1504. doi: 10.1515/cclm-2012-0585
|
[15] |
DEL BENE A, CIOLLI L, BORGHERESI L, et al. Is type 2 diabetes related to leukoaraiosis? an updated review[J]. Acta Neurol Scand, 2015, 132(3): 147-155. doi: 10.1111/ane.12398
|
[16] |
POLLAK M. Insulin and insulin-like growth factor signalling in neoplasia[J]. Nat Rev Cancer, 2008, 8(12): 915-928. doi: 10.1038/nrc2536
|
[17] |
CLEMMONS D R, MAILE L A, LING Y, et al. Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress[J]. Growth Horm IGF Res, 2007, 17(4): 265-270. doi: 10.1016/j.ghir.2007.01.004
|
[18] |
DONATH M Y, SCHUMANN D M, FAULENBACH M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy[J]. Diabetes Care, 2008, 31(Suppl 2): S161-S164. http://www.ncbi.nlm.nih.gov/pubmed/18227479
|
[19] |
LOEB S, GONZALEZ C M, ROEHL K A, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening[J]. J Urol, 2006, 175(3 pt 1): 902-906. http://europepmc.org/abstract/MED/16469576
|